INLB: AI 评分 45/100 — AI 分析 (4月 2026)

Item 9 Labs Corp. is a vertically integrated cannabis operator and dispensary franchisor in the United States. The company produces and distributes a range of cannabis products through its own dispensaries and franchise network, primarily in Arizona.

Key Facts: AI Score: 45/100 Sector: Healthcare

公司概况

概要：

Item 9 Labs Corp. operates as a vertically integrated cannabis company, producing and distributing cannabis products through its dispensaries and franchised Unity Rd locations. Focused on the Arizona market, the company navigates the evolving regulatory landscape of the specialty and generic drug manufacturing sector.

INLB是做什么的？

Item 9 Labs Corp., headquartered in Phoenix, Arizona, is a vertically integrated cannabis operator and dispensary franchisor. The company cultivates, processes, and retails cannabis and cannabis-related products. Its operations span various product categories, including flower, concentrates, distillates, and hardware. Item 9 Labs distributes its products through its own licensed dispensaries and through franchised locations operating under the Unity Rd brand. The company focuses primarily on the Arizona market, catering to both medical and adult-use cannabis consumers. Its business model integrates cultivation, manufacturing, distribution, and retail sales, allowing for greater control over product quality and supply chain efficiency. Item 9 Labs also seeks to expand its footprint through franchising, offering entrepreneurs the opportunity to operate cannabis dispensaries under a recognized brand. The company's vertically integrated approach aims to capture a larger share of the cannabis value chain, from seed to sale. The company's strategy involves expanding its dispensary network and product offerings to meet the growing demand for cannabis products in Arizona and beyond.

INLB的投资论点是什么？

Item 9 Labs Corp. presents a unique investment opportunity within the cannabis sector due to its vertically integrated business model and dispensary franchising strategy. The company's focus on the Arizona market, combined with its Unity Rd franchise network, positions it for growth as the cannabis industry matures. However, the may be worth researching risks associated with operating in a highly regulated and competitive market. With a negative P/E ratio and a negative profit margin of -143.1%, the company's profitability is a concern. Key growth catalysts include expansion of the dispensary network and increased brand recognition. The company's gross margin of 33.6% indicates potential for improved profitability with scale. The company's beta of 0.15 suggests low volatility relative to the market.

INLB在哪个行业运营？

Item 9 Labs Corp. operates within the rapidly evolving cannabis industry, which is characterized by increasing legalization and growing consumer demand. The market is highly competitive, with numerous companies vying for market share. The company's vertically integrated model and franchise strategy differentiate it from some competitors, but it also faces challenges from larger, well-capitalized players. The industry is subject to significant regulatory uncertainty, which can impact operations and profitability. The company's focus on the Arizona market provides a degree of geographic concentration, but also exposes it to state-specific regulatory risks.

Drug Manufacturers - Specialty & Generic

Healthcare

INLB有哪些增长机遇？

Expansion of Dispensary Network: Item 9 Labs Corp. can expand its revenue by opening new dispensaries in Arizona and other states where cannabis is legal. The legal cannabis market is projected to reach $50 billion by 2026, providing a significant growth opportunity for companies with established retail networks. The company's Unity Rd franchise model offers a capital-efficient way to expand its footprint. This expansion could be executed over the next 3-5 years.
Product Innovation and Diversification: Item 9 Labs Corp. can drive growth by introducing new cannabis products and expanding its product offerings. The company can focus on developing innovative products that cater to specific consumer needs and preferences. This could include new strains of cannabis, edibles, topicals, and other cannabis-derived products. The timeline for this growth opportunity is immediate and ongoing.
Strategic Partnerships and Acquisitions: Item 9 Labs Corp. can accelerate its growth by forming strategic partnerships with other companies in the cannabis industry. This could include partnerships with cultivators, processors, distributors, and retailers. The company can also pursue acquisitions of complementary businesses to expand its product offerings and market reach. The timeline for this growth opportunity is within the next 2-3 years.
Brand Building and Marketing: Item 9 Labs Corp. can invest in building its brand and marketing its products to increase brand awareness and customer loyalty. The company can use a variety of marketing channels, including social media, digital advertising, and traditional advertising. The company can also sponsor events and participate in industry trade shows to promote its brand. The timeline for this growth opportunity is immediate and ongoing.
Franchise Expansion: Item 9 Labs Corp. can significantly grow its revenue by expanding its Unity Rd franchise network across multiple states. The company can target states with favorable cannabis regulations and a strong demand for cannabis products. This expansion can be achieved through targeted marketing campaigns and by offering attractive franchise terms to potential franchisees. The timeline for this growth opportunity is within the next 3-5 years.

Vertically integrated operations provide control over the entire cannabis value chain, from cultivation to retail.
Franchise model through Unity Rd offers a scalable approach to expanding dispensary network.
Focus on the Arizona market allows for targeted marketing and distribution strategies.
Gross margin of 33.6% indicates potential for profitability improvements.
Negative profit margin of -143.1% highlights the need for improved cost management and revenue growth.

INLB提供哪些产品和服务？

Cultivates cannabis plants.
Processes cannabis into various products like flower, concentrates, and distillates.
Manufactures cannabis-related hardware.
Operates licensed cannabis dispensaries in Arizona.
Sells medical and adult-use cannabis products.
Franchises cannabis dispensaries under the Unity Rd brand.

INLB如何赚钱？

Vertically integrated operations from cultivation to retail sales.
Generates revenue through direct sales at company-owned dispensaries.
Earns franchise fees and royalties from Unity Rd franchisees.

Medical cannabis patients in Arizona.
Adult-use cannabis consumers in Arizona.
Entrepreneurs seeking to operate cannabis dispensaries through the Unity Rd franchise program.

Vertically integrated operations provide cost advantages and quality control.
Unity Rd franchise network offers a scalable expansion model.
Established presence in the Arizona cannabis market.

什么因素可能推动INLB股价上涨？

Upcoming: Expansion of dispensary network through new openings and franchise growth.
Ongoing: Increasing legalization of cannabis in additional states, creating new market opportunities.
Ongoing: Product innovation and development of new cannabis-derived products.
Upcoming: Potential strategic partnerships or acquisitions to expand market reach.
Ongoing: Brand building and marketing efforts to increase brand awareness and customer loyalty.

INLB的主要风险是什么？

Potential: Regulatory uncertainty and changes in cannabis laws.
Ongoing: Intense competition from other cannabis companies.
Potential: Fluctuations in cannabis prices and supply.
Ongoing: Negative profitability and the need for improved cost management.
Potential: Limited access to capital and financing challenges.

INLB的核心优势是什么？

Vertically integrated operations
Franchise model for expansion
Established presence in Arizona
Diverse product offerings

INLB的劣势是什么？

Negative profitability
Limited geographic diversification
Reliance on a single state market (Arizona)
Small market capitalization

INLB有哪些机遇？

Expansion into new states
Product innovation and diversification
Strategic partnerships and acquisitions
Increasing legalization of cannabis

INLB面临哪些威胁？

Regulatory uncertainty
Intense competition
Fluctuations in cannabis prices
Changing consumer preferences

INLB的竞争对手是谁？

BioHarvest Sciences Inc. — Focuses on nutraceutical and functional food applications of plant cell technology. — (BIOIF)
Canna-Global Acquisition Corp. — A special purpose acquisition company (SPAC) focused on the cannabis industry. — (CBGL)
Greenrose Holding Company Inc — Operates as a vertically integrated cannabis company with cultivation, processing, and retail operations. — (GREH)
Hemp, Inc. — Focuses on hemp-based products and services. — (HENC)
Isodiol International Inc — Develops and markets cannabidiol (CBD) products. — (ISOLF)

Key Metrics

MoonshotScore: 45/100

Company Profile

CEO: Jeffrey I. Rassas
Headquarters: Phoenix, US
Employees: 97
Founded: 2012

AI Insight

AI analysis pending for INLB

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Item 9 Labs Corp. do?

Item 9 Labs Corp. operates as a vertically integrated cannabis company, handling everything from cultivation and processing to retail sales and franchise operations. The company produces a range of cannabis products, including flower, concentrates, and distillates, which are sold through its own dispensaries and franchised Unity Rd locations. The company primarily focuses on the Arizona market, serving both medical and adult-use cannabis consumers. Its vertically integrated approach allows for greater control over product quality and supply chain efficiency, while its franchise model provides a scalable avenue for expansion.

What do analysts say about INLB stock?

As of March 16, 2026, there is no readily available analyst coverage or consensus on Item 9 Labs Corp. (INLB) stock, likely due to its OTC listing and small market capitalization. Investors should conduct their own thorough research and due diligence before considering an investment in INLB. Key valuation metrics, such as price-to-earnings ratio, are currently not meaningful due to the company's negative profitability. Growth considerations include the company's ability to expand its dispensary network and improve its financial performance.

What are the main risks for INLB?

Item 9 Labs Corp. faces several risks inherent to the cannabis industry, including regulatory uncertainty, intense competition, and fluctuations in cannabis prices. The company's reliance on the Arizona market exposes it to state-specific regulatory risks. Its negative profitability and small market capitalization also present financial challenges. As an OTC-listed company, INLB is subject to less stringent regulatory oversight and may have limited liquidity, increasing the risk for investors. Investors should carefully consider these risks before investing in INLB.